Treatment of Cellulitis in Diabetic Patients

Clinical Decision Algorithm

The American College of Physicians recommends clindamycin as the most appropriate empiric choice for diabetic patients with cellulitis, as it covers both streptococci and MRSA without requiring combination therapy 1
Key MRSA risk factors to assess in diabetic patients with cellulitis include penetrating trauma or injection drug use, purulent drainage or exudate, evidence of MRSA infection elsewhere or nasal colonization, systemic inflammatory response syndrome (SIRS), and failure of prior beta-lactam therapy 1, 2
Hospitalization criteria in diabetic patients with cellulitis include SIRS, altered mental status or hemodynamic instability, concern for necrotizing infection, and severe immunocompromise 1, 2, 3

Clindamycin is the optimal choice for diabetic patients with cellulitis, providing single-agent coverage for both streptococci and MRSA without requiring combination therapy, with a cure rate of 86% in diabetic patients with complicated infections 1, 3
Vancomycin is reserved for hospitalized patients with complicated cellulitis requiring IV therapy, with a recommended dose of 15-20 mg/kg IV every 8-12 hours 1
Meropenem represents significant overtreatment for typical cellulitis and should be reserved for severe infections with systemic toxicity requiring broad-spectrum combination therapy, suspected necrotizing fasciitis, or documented resistant organisms 1

The Infectious Diseases Society of America recommends treating diabetic patients with cellulitis for 5 days if clinical improvement occurs, with extension of treatment only if symptoms have not improved 1
Improvement of glycemic control aids in both eradicating infection and healing wounds in diabetic patients 4
Essential adjunctive measures for diabetic patients with cellulitis include elevating the affected extremity, examining interdigital toe spaces, treating predisposing conditions, and avoiding systemic corticosteroids 1, 2, 3